Objectives: The present study aimed to validate the new international guidelines for IPMN and determine the surgical criteria for patients with IPMN exhibiting high-risk stigmata (HRS). Methods: We enrolled 115 IPMN patients exhibiting HRS who were diagnosed between 2004 and 2021. Of the 115 patients, 79 underwent surgery (surgical group) and 36 did not undergo surgery (non-surgical group). The overall survival (OS) of each group was compared, and multivariate analysis was performed to identify factors associated with OS. Results: There was no significant difference in the estimated 5-year OS in the surgical and non-surgical groups (67% vs. 74%; p = 0.75). The presence of a solid component (SC) (hazard ratio [HR], 6.92; 95% confidence interval [CI], 3.30–14.5) and a high score of age-adjusted Charlson comorbidity index (ACCI) (≥5) (HR, 2.27; 95% CI, 1.11–4.64) were independent predictors of poor OS. In the presence of an SC, the surgical group had a significantly better OS than the non-surgical group (estimated 5-year OS, 38% vs. 18%; p = 0.031). In the absence of an SC, the prognosis of patients with a high ACCI was significantly poorer than those with a low ACCI in the surgical group (estimated 5-year OS, 59% vs. 93%; p = 0.005). Conclusions: An SC and a high ACCI are important prognostic factors in IPMN patients exhibiting HRS. Thus, patients with an SC should undergo surgical resection. However, conservative management may be the optimal treatment in patients without an SC and with a high ACCI.
Background: Atezolizumab plus bevacizumab (AB) is a standard first‐line therapy for unresectable hepatocellular carcinoma (HCC). However, data on the efficacy and safety of AB rechallenge (re‐AB) after discontinuation are limited. Methods: We conducted a retrospective analysis of 13 patients with unresectable HCC who received initial AB treatment and re‐AB at the University of Yamanashi and Fujita Health University. Rechallenge was defined as reinitiating AB after prior discontinuation followed by one or more other systemic therapies. Tumor responses were assessed using RECIST v1.1 and modified RECIST (mRECIST), and adverse events (AEs) were evaluated according to CTCAE v5.0. Results: During initial AB, the objective response rate (ORR), disease control rate (DCR), and median progression‐free survival (mPFS) were 15%, 69%, and 3.7 months, respectively. AB was discontinued due to disease progression or immune‐related AEs. Re‐AB was administered after a median of two intervening regimens. In the re‐AB phase, ORR, DCR, and mPFS were 15%, 54%, and 4.7 months, respectively. Despite prior progression, two patients achieved partial response and five had stable disease. No worsening of previously observed AEs occurred during re‐AB. Conclusions: AB rechallenge may be a safe and potentially effective treatment option for selected patients with unresectable HCC, even after discontinuation due to disease progression or adverse events.
Aim: Weight loss (WL) is important for improving steatotic liver. However, there have been no sufficient reports comparing WL with liver fibrosis and steatotic changes using magnetic resonance imaging (MRI).Methods: The study included 111 patients with metabolic dysfunction associated steatotic liver disease who did not take any new drugs during the study period. They were evaluated using MRI and FibroScan®, and then were given a mild low‐carbohydrate diet. One year later, they were evaluated again, and changes in alanine transaminase (ALT), MRI proton density fat fraction (MRI‐PDFF), and magnetic resonance elastography were examined.Results: The patients achieved an average WL of 4.2 kg. MRI‐PDFF was significantly improved by 0.68‐fold for 5%–7% WL, 0.61‐fold for 7–10 %WL, and 0.35‐fold for 10% or more WL (vs. gain: p < 0.01). In patients with a WL of 5% or more, magnetic resonance elastography was decreased. MRI‐PDFF reduction of 30% was observed in 56% of patients with 5%–7% WL, 75 % with 7%–10% WL, and 94% with 10% or more WL (p < 0.01). ALT normalization or 30% reduction was well associated with WL, with 73% for 5%–7% WL, 64% for 7%–10% WL, and 93% for 10% or more WL (p < 0.01). The optimal cutoff for MRI‐PDFF improvement and ALT improvement was 5.3% WL in both tests according to receiver operating characteristic analysis (p < 0.01).Conclusions: Many patients achieved improvement in MRI‐PDFF and ALT with WL. WL of 5.3% can improve MRI‐PDFF and ALT, contributing to a better prognosis for metabolic dysfunction associated steatotic liver disease patients.
Background and Aims: Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such cases remain unclear. This nationwide, multicenter, prospective study aimed to evaluate the efficacy of retreatment regimens in patients who failed initial DAA therapy. Methods: A total of 330 patients were enrolled, including 117 with prior GLE/PIB failure and 213 with prior SOF/LDV failure. The primary outcome was sustained virologic response at 12 weeks after retreatment (SVR12). Retreatment regimens included 12 weeks of GLE/PIB, sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV), or SOF/LDV. Results: Among patients retreated after GLE/PIB failure, SVR12 rates were 99.0% (98/99) with SOF/VEL + RBV, 92.3% (12/13) with GLE/PIB 12 weeks, and 100% (5/5) with SOF/LDV, with no significant differences among regimens. Among patients retreated after SOF/LDV failure, SVR12 rates were 100% (12/12) with SOF/VEL + RBV, 99.5% (197/198) with GLE/PIB 12 weeks, and 66.7% (2/3) with SOF/LDV. Retreatment of SOF/VEL + RBV or GLE/PIB demonstrated high therapeutic efficacy in patients with prior SOF/LDV failure. One patient who relapsed after GLE/PIB 8‐week therapy and harbored a P32del mutation achieved SVR12 with SOF/VEL + RBV retreatment. Conclusions: Retreatment with SOF/VEL + RBV, GLE/PIB for 12 weeks, or SOF/LDV achieved high SVR12 rates, indicating that effective viral eradication is feasible using currently available DAA regimens even after prior treatment failure.
Local ablation therapies are important treatment options for early-stage hepatocellular carcinoma (HCC). Various techniques have been used to perform these therapies efficiently and safely. However, few reports have discussed the usefulness of body position change (BPC). This study aimed to investigate the usefulness of BPC during local ablation therapies in patients with HCC. We evaluated 283 HCC nodules that underwent local ablation therapy. These nodules were categorized into high- or low-risk locations on the basis of their proximity to large vessels, adjacent extrahepatic organs, or poor visibility under ultrasound (US) guidance. The technical success rates, procedure time, and prognosis were evaluated. In this study, 176 (62%) nodules were classified in the high-risk location group. The high-risk location group was treated with techniques such as BPC, artificial pleural fluid, artificial ascites, fusion imaging, and contrast-enhanced US more frequently than the low-risk location group. The technical success rates were 96% and 95% for the high- and low-risk location groups, respectively. Within the high-risk location group, those without BPC had a lower success rate than those with BPC (91% vs. 99%, p = 0.015). Notably, BPC emerged as the sole contributing factor to the technical success rate in the high-risk location group (OR = 10, 95% CI 1.2–86, p = 0.034). In contrast, no differences were found in the procedure time, local tumor progression rates, intrahepatic distant recurrence rates, and overall survival between the groups with and without BPC in the high-risk location group. In conclusion, BPC during local ablation therapy in patients with HCC in high-risk locations was safe and efficient. The body position should be adjusted for HCC in high-risk locations to maintain good US visibility and ensure a safe puncture route in patients undergoing local ablation therapies.